News

Mr Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide evidence based medicine function for the ortho-clinical diagnostics

The terms of the licensing agreement provide for payments to Rosetta, either as milestones or R&D funding, as well as royalty payments on net sales in the US.

India-based Glenmark Pharmaceuticals has reported that its candidate for neuropathic pain, osteoarthritis and other inflammatory pain disorders – GRC 10693, has successfully completed Phase I trials in Europe.

Suven Life Sciences, an Indian drug discovery and development company, has completed its Phase I multiple ascending dose study of SUVN-502 in healthy volunteers. SUVN-502 is reported to

Xoft, a developer of electronic brachytherapy systems, has received a medical device license from the Medical Devices Bureau of Health Canada to sell and market the Axxent electronic

The company reported net sales of $615 million for the three months ended February 28, 2009, an increase of 2%, compared to $603.1 million for the three months

The contract, valued at GBP1.1 million, is for process development and GMP manufacture of specific antibodies. This contract will be delivered by mid-2010. The company also signed a

Mr Hawkins spent the past seven years in founder and leadership roles developing and commercializing medical devices for incubators funded by Three Arch Partners, Frazier Healthcare, Prospect Ventures,

In addition to reducing the size of its management team, the company announced that Bernard Boudreau, Edgar Parker, Aditya Jah, Vasu Chanchlani and Michael Sefton have all resigned